As many therapeutic RNA oligonucleotides including small interference RNAs (siRNAs) and antisense oligonucleotides, are being developed to target many disease genes that were once considered undruggable (Chery, 2016; Dammes & Peer, 2020; Sehgal et al., 2013), combining gene knockdown with RIG‐I activation is an attractive approach for anti‐cancer therapy. Here, RIGI is linked to cancer.